Compound AC220

DRUG2 trials

Sponsors

Daiichi Sankyo

Conditions

Acute Myeloid LeukemiaSolid Tumors

Phase 1

Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors

CompletedNCT01049893

Daiichi SankyoSolid Tumors

Start: 2010-01-31End: 2011-11-30Updated: 2019-02-12

Phase 2

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

CompletedNCT00989261

Daiichi SankyoAcute Myeloid Leukemia

Start: 2009-11-30End: 2014-12-31Updated: 2019-12-11

Related Papers

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.

2018-08-069 citations

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

2018-05-31202 citations

Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with <i>FLT3</i>-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.

Journal of Clinical Oncology2018-05-202 citations

Differentiation Response to Quizartinib, a Potent 2nd Generation FLT3 Inhibitor, in Relapsed FLT3 -Mutant AML Patients Correlates with Specific DNA Methylation Signature Prior to Therapy

Blood2017-12-081 citations

The benefit of treatment with quizartinib and subsequent bridging to HSCT for FLT3-ITD(+) patients with AML.

Journal of Clinical Oncology2014-05-209 citations